Mirum Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-29.
Mirum Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 29, 2026. The filing reports $68.48M sold. Its industry group is Biotechnology. It names Christopher Peetz (Executive Officer, Director), Eric Bjerkholt (Executive Officer), Peter Radovich (Executive Officer) (SEC Form D, January 29, 2026).
Sell to companies like Mirum Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-01-29 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Mirum Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Mirum Pharmaceuticals, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in January 2026, largest first.
Get an email when Mirum Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Mirum Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Mirum Pharmaceuticals, Inc. →Get the full cited report on Mirum Pharmaceuticals, Inc.
What the filing shows about Mirum Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Mirum Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Mirum Pharmaceuticals, Inc. See pricing
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $68.48M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Christopher Peetz is named as Executive Officer and Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Eric Bjerkholt is named as Executive Officer on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Peter Radovich is named as Executive Officer on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Laura Brege is named as Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Timothy Walbert is named as Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
William Fairey is named as Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Patrick Heron is named as Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Lon Cardon is named as Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Saira Ramasastry is named as Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Laurent Fischer is named as Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
Michael Grey is named as Director on the Form D that Mirum Pharmaceuticals, Inc. filed with the SEC on 29 January 2026, one of 11 people that filing names.
11 people named on the filing — 3 holding an executive role and 8 as directors only.
Named as of the 2026-01-29 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Mirum Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Mirum Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mirum Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Mirum Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Mirum Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Mirum Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
https://mentionfox.com/funding/mirum-pharmaceuticals-inc-form-d-26000001